Find and Pitch Jounalists, Get Your Story Covered

Tags: hardware robotics startups funding industrial robotics

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 27 days ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds - 5 months ago STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 12 months ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - about 1 year ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - over 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago
2	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	With uncertainty roiling Big Pharma, execs are placing lower-risk bets - 3 months ago By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years - 3 months ago Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A? - 3 months ago How pharma was instrumental in President Jimmy Carter’s global health efforts - 4 months ago Big Pharma earnings hang hope on the next generation of blockbusters - 6 months ago 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - 6 months ago Why pharma megamergers may become a relic of the past - 6 months ago Top pharma and biotech conferences 2025 - 7 months ago Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half - 9 months ago Has pharma emerged from the ‘age of uncertainty’? - 9 months ago Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections - 10 months ago As Big Pharma places bigger bets on ADCs, here’s where the field is headed next - 11 months ago AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets - 11 months ago How pharma’s surging M&A is impacting the industry’s tech sector - about 1 year ago Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps - about 1 year ago How to make 2024 a banner year for biopharma, despite the headwinds - over 1 year ago Pharma’s financial market will be a tale of two cities in 2024 - over 1 year ago Biopharma’s FTC headache deepens with guideline shifts years in the making - over 1 year ago Real Chemistry’s CEO on biopharma’s outlook in 2024 - over 1 year ago How pharma leaders talk about ethics in a highly criticized industry - over 1 year ago The thorniest questions facing pharma, according to a leading bioethicist - over 1 year ago How Big Pharma keeps the oncology engines hot with a host of strategies - over 1 year ago The PharmaVoice 100: Rare disease warriors - over 1 year ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D - 3 months ago Pharma’s forecast for 2025: Sowing seeds of a rebound - 3 months ago Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking - 3 months ago The ability to pivot will be ‘key’ as pharma’s tariff threat looms - 3 months ago PharmaVoice’s Crystal Ball: The industry’s AI future - 4 months ago 3 closely watched drugs that failed in the clinic - 4 months ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 6 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - 6 months ago 2024 PharmaVoice 100s: Trailblazers - 6 months ago What 3 layoff stories reveal about pharma’s troubles - 8 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 8 months ago Is anyone taking the world’s priciest drugs? - 8 months ago What pharma has learned from AI - 9 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 11 months ago Where competition is heating up in pharma - 11 months ago The biggest questions hanging over pharma in 2024 - about 1 year ago Pharma execs sound off on trends and policies they’re tracking in 2024 - over 1 year ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - over 1 year ago 3 standout digital innovations in pharma this year - over 1 year ago PharmaVoice 100s: Entrepreneurs - over 1 year ago PharmaVoice 100s: Clinical trial gurus - over 1 year ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Oncology, obesity and more: Where pharma R&D is headed in 2025 - 4 months ago From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies - 5 months ago M&A is ready to explode, and that’s good news for pharma layoffs - 8 months ago As the GLP-1 market booms, other healthcare companies are cashing in - 10 months ago As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene - about 1 year ago
5	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 months ago
6	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 months ago
7	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 months ago
8	Beth Mole Ars Technica Senior Health Reporter @ArsTechnica. microbiologyinfectious diseasespublic health	Big Pharma’s fight against drug price reforms takes weird, desperate turn - 10 months ago
9	Kelly Bilodeau Pharma Voice Mom, wife, freelance writer. writing	Pharma has a misinformation problem — and execs could be on the hook - about 1 year ago Pharma takes a gut check of microbiome drugs - over 1 year ago What are pharma’s next blockbusters? - over 1 year ago Oncology drugmakers seek the sweet spot between efficacy and tolerability - over 1 year ago Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline. - over 1 year ago From the rainforest to Wall Street — Jaguar Health’s big play for revitalization - over 1 year ago
10	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	2024 - over 1 year ago

Journalists covering pharma industry